Search

Our Two-Second Indicator remains negative, our Cabot Tides are now on the fence, and the breadth-related yellow flags have led to some strong selling this week. Short-term, it’s best to pare back on any stocks that break down; longer-term, though, we remain optimistic.

As Warren Buffett said, “Long ago, Ben Graham taught me that ‘Price is what you pay; value is what you get.’ Whether we’re talking about socks or stocks, I like buying quality merchandise when it is marked down.” Two stocks that I think Mr. Buffett should own are Johnson Controls and Whirlpool.

The market has been doing OK, though it’s more about addition by subtraction—the fact that growth stocks have avoided any major selling wave after the recent upmove is a plus, but we’re still seeing lots of selling on strength and rotational action that changes by the day.

The fourth company on my list of stocks that share growth and value characteristics is Gilead Sciences.

Apple (AAPL), Baidu (BIDU), Google (GOOG) and Netflix (NFLX) are overviewed by the editor.

The market continues to be a bit sketchy, and the S&P 600 Small Cap Index is still trading right around the 820 level, which has served as a rough support line thus far this year.

Trim your sails a bit and see how the market handles itself going forward. Today’s whopping decline isn’t the end of the world for growth stocks, but the broad market is more worrisome, with the Cabot Tides now neutral and our Two-Second Indicator turning negative.

The market continues to act “fine” as we get a little deeper into earnings season this week.

At the index level, small-cap stocks are unremarkable. But I continue to attribute the underperformance to the high weight of rate-sensitive sectors (financials, energy, industrials, materials).

The holiday-shortened week was mostly a non-event as the S&P 500, Dow and Nasdaq were mostly mixed. And while the week was quiet, under the surface there was selling pressure in growth stocks and materials that raised some yellow flags.

The holiday-shortened week was mostly a non-event as the S&P 500, Dow and Nasdaq were mostly mixed. And while the week was quiet, under the surface there was selling pressure in growth stocks and materials that raised some yellow flags.

Markets pulled it together last week, with oversold financial and consumer stocks finding support and delivering gains for the holiday-shortened week. However, the market started this week with another sharp pullback Monday, bringing the Dow and S&P 500 back to their February lows. And markets look set to open lower today after China announced a slew of retaliatory 25% tariffs on U.S. exports. A rebound later this week is likely, but not certain.

We’re going to reel in a few profits during this post-election stock market surge in the event the honeymoon is short-lived. Along those lines, today I recommend you sell your remaining stake in Mitek (MITK), as well as sell half your position in LeMaitre Vascular (LMAT) and NanoString (NSTG).

After a stunningly strong market so far this year, with the S&P 500 producing a 20% total return through Monday, the slow grind-down of most stocks since early September has seemed interminable. The 1,100 largest stocks in our 3,000-stock database have declined only 2% in the past two weeks, but the steady flow of higher inflation news, a growing likelihood of interest rate increases, a never-ending pandemic, the prospect of higher taxes of all kinds and memories of the tragic events of 9/11 makes us feel like we’re stuck inside on a cold, rainy day watching an awful four-hour movie.

For anyone engaged in the forecasting business, the temptation is always present to make a sensational claim about the future in order to stand out from the crowd and garner mainstream media attention. And truth be told, for those of us whose livelihoods involve predicting financial markets, that temptation must often be suppressed in the interest of professionalism.

It’s time to buy stocks more aggressively.

That’s the case for stocks in general, but also cannabis stocks. Most cannabis companies aren’t really affected by tariffs. But their stocks have been hit recently by the shift to “risk-off” mode among investors.

The flip of the calendar has brought some wild action, and overall, growth stocks and funds remain stuck in the mud, unable to make much progress (even including the Nasdaq itself). We remain cautious right now and, in fact, are placing two of our stocks on Hold today as they’ve been weighed down by the environment. That said, while we’re holding lots of cash, we remain flexible, as tons of names are in consolidations and are presenting at key conferences (which have become like earnings reports at times) next week—if we see many breakouts, we’ll pounce, but for now, we advise a bit more patience.

In uncertain times like these, it’s only natural that defensive-minded investors are gravitating to healthcare stocks. After all, this space is characterized by consistent demand for essential products and services that millions rely on, regardless of the state of the economy. (Additionally, many of the companies in this category offer dividends that can be considered quite attractive during market sell-offs.)


While the sector itself has only lately returned to favor, a number of consumer-facing healthcare companies remain out of Wall Street’s good graces and under the public’s radar—including some which provide critical staple products for the everyday needs of consumers.

One of those companies is today’s turnaround recommendation.

In tonight’s issue, we details our recent moves and our thinking, as well as update the track record of our most reliable market timing indicator. We also talk about one of our favorite growth stocks we don’t own which, after a four-year (!) consolidation, looks like it could be ready to turn.

The market has followed through on last week’s rebound rally and we’re seeing an increasing number of strong growth stocks with good setups. The big news is that the rally has lifted many of the indexes we follow above their 25- and 50-day moving averages, giving us a green light for new buying. We don’t advise jumping in with both feet—new buy signals do not guarantee a continued advance—but you should be taking a serious inventory of your watch list (and the stocks in this week’s issue) to select a few favorites for buying.
This week’s list includes several bigger names and a few recent IPOs, which indicates good breadth for the rally. Our favorite is SunPower (SPWR), which is making the turnaround in the solar industry look like a sound growth proposition.

Stock Name	Price	Buy Range	Loss Limit
SunPower (SPWR)	12.26	19.5-22	17-18
Splunk (SPLK)	207.67	45-47	41-42
Proto Labs (PRLB)	0.00	63-65	55-56
The Priceline Group Inc. (PCLN)	0.00	810-840	779-780
Illumina Inc. (ILMN)	289.74	72-74	67-68
Ciena (CIEN)	44.25	19-20	17.5-18
Bloomin’ Brands (BLMN)	0.00	24-25	22.5-23
Boeing (BA)	432.22	99-102	94-95
American Axle (AXL)	0.00	17.5-18.5	16-16.5
Actavis (ACT)	0.00	123-127	108-110

After 16 relatively smooth weeks, the sellers have finally put up a fight this week, dragging most growth stocks down after big runs. We trimmed a bit earlier this week, selling one name and taking partial profits in another, leaving us with 20% in cash. But most of the evidence remains positive, and while we remain flexible, we’re comfortable giving most of our winners a chance to digest their recent moves.

This week’s issue writes about why a market pullback would make sense around here, but also talks about the most bullish factor we see (lots of early-stage leaders out there). And, as always, we give you all our latest ideas and thoughts on the market and our stocks, including key levels we’re watching.